Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Sections
Personal tools
Log in
You are here: Home About EDRN Participating Sites University of Pittsburgh Cancer Institute

University of Pittsburgh Cancer Institute

Serum Biomarkers for Colon Cancer

Objective

Develop and validate nuclear matrix proteins as biomarkers for early detection of colon cancer.

Program Description

An integrated multi-disciplinary approach will be used to identify biomarkers for colorectal cancer. The team includes basic cancer researchers and clinicians supported by faculty with expertise in biostatistics/bioinformatics.

Specific Aims

  • Characterize, evaluate, and validate a set of unique nuclear matrix proteins (NMPs) which are expressed in colorectal cancer.
  • Undertake an extensive Phase 1 and 2 validation study to assess the performance of the NMP biomarker, CC2, for serum-based early detection of colorectal cancer.
  • Characterize and evaluate other NMPs, with varying spectrums of expression in pre-malignant (adenomas) and malignant tissue, as potential biomarkers of early disease and/or risk.

Contact Information

Bigbee, William

University Of Pittsburgh Cancer Institute
> 305 Iroquois Bldg.<br> 200 Lothrop St.
> Pittsburgh, PA 15213<br> Tel: (412) 967-6534
> Fax: (412) 967-6576<br> Email: bigbeewl@msx.upmc.edu